Cannabis Bioscience International Holdings Inc

Publicly traded company advancing cannabinoid science through clinical innovation, therapeutic development, and medical research. OTC: $CBIH

[Cannabis Bioscience International Holdings Inc @CBIHMD]

CBIH Advances Strategic Pathway to Bring VitaCookies’ Science-Driven Functional Wellness Platform to Texas Consumers

HOUSTON, Texas — June 8, 2026 — Cannabis Bioscience International Holdings, Inc. (OTC Markets: CBIH), a public biotechnology company trading under the ticker symbol CBIH, today announced that it has completed and submitted the required documentation as part of its Texas licensing process related to the planned commercialization of VitaCookies, its cannabinoid-formulated functional wellness cookie line. CBIH intends to move forward carefully, with a focus on licensing and franchising opportunities, appropriate commercialization structures, product standards, quality control, and responsible market entry.

VitaCookies has been developed over nearly two years of structured research and formulation work by CBIH’s multidisciplinary research and development team, including physicians, scientists, Ph.D. chemists, Ph.D. biologists, and pharmacists. “Proper nutrition is fundamental to the body’s normal biological function, metabolic balance, immune support, and overall wellness. When nutrition is not properly addressed, the body cannot perform at its full functional capacity,” said Rosangel Andrades, M.D., CBIH R&D Director. “Guided by this principle, the formulation process incorporated a nutrition-focused product design approach, evaluating ingredient function, nutrient profile, compatibility, safety profile, sensory performance, flavonoid and terpenoid relevance where appropriate, cannabinoid interactions, dosage strategy, flavor behavior, and consumer usability before advancing the product line.”

Read the full release:
https://t.co/4cCdAWUMc6
$CBIH #CannabinoidScience #Biotech #MedicalResearch #CannabinoidBiotechnology

[Cannabis Bioscience International Holdings Inc @CBIHMD]

Federal cannabis reform is moving into a more serious phase.

Rescheduling is important, but it should be viewed as part of a broader transition toward research access, regulatory clarity, product standards, safety evaluation, and responsible implementation.

That is where long-term industry credibility will be built.

$CBIH #CannabisPolicy #MedicalCannabis #CannabinoidScience #Biotech

[Anthony Martinelli @AMartinelliWA]

Federal legislation to deschedule cannabis has gained another sponsor in the U.S. House, bringing the bill to 74 sponsors overall and marking the 12th new sponsor since the DOJ signed its marijuana rescheduling order in April. https://t.co/NmrJZzTLOx

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@NORML @TheUSSCgov State-level legalization has changed the enforcement landscape, but the federal framework still needs to catch up.

Long-term cannabis policy should focus on regulatory clarity, public safety, compliance, product standards, and responsible implementation.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

A major policy or market event may create attention, but long-term value will depend on what the sector builds after it.

Cannabis companies will need regulatory discipline, science-driven execution, product standards, safety, and credibility to mature beyond short-term market cycles.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

The conversation around medical cannabis and opioid-related public health should not be reduced to slogans.

It requires evidence, public health data, physician oversight, safety standards, and responsible regulatory frameworks.

Responsible healthcare policy requires serious scientific evaluation.

$CBIH #MedicalCannabis #CannabinoidScience #HealthcarePolicy #Biotech

[Jeremy Foster Berke @jfberke]

State medical and recreational cannabis laws are associated with a 15.47% and 11.92% reduction in non-fatal opioid poisonings per 100,000 insurance enrollees per quarter, according to a new study in Preventive Medicine Reports.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

Cannabinoid-derived medicines entering regulated pharmaceutical pathways should be evaluated through clinical evidence, safety standards, physician oversight, and responsible regulatory frameworks.

As this field advances, long-term credibility will depend on rigorous science, consistency, and careful implementation.

$CBIH #CannabinoidScience #MedicalCannabis #Biotech #HealthcarePolicy

[Bloomberg @business]

A cannabis-derived drug for lower back pain will soon go on sale in Germany and Austria in what its developer views as a dry run for launching in the world’s biggest pharma market: the US https://t.co/GY38VqGsY8

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@V_arrell Cannabis policy should move beyond stigma and moral framing.

The stronger conversation is about responsible regulation, scientific standards, consumer safety, medical access where appropriate, and clear frameworks that protect both patients and markets.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@FlowhubCo The decline in federal cannabis prosecutions shows how quickly the policy landscape is changing.

The next step is building regulated frameworks with clear rules, safety standards, compliance, consumer protection, and responsible implementation.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@DescheduleEarth Federal cannabis reform should move with regulatory clarity and responsible implementation.

Clear rules, scientific standards, consumer safety, product consistency, and workable compliance frameworks are essential for building a credible long-term market.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@anandastrategy @mogreenway @mimcammj Market data matters because it shows where regulated cannabis is gaining traction.

The next step for long-term credibility is making sure growth is supported by product standards, testing, consumer safety, compliance, and responsible oversight.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@CarverJohns Medical cannabis policy should continue to be discussed through evidence, patient access, safety, and responsible clinical frameworks.

As research and regulation evolve, healthcare conversations need clarity, standards, and careful implementation.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@todd_harrison Legal market growth is important, but long-term credibility depends on how regulated markets mature.

Product standards, testing, labeling, consumer safety, and responsible oversight are what help cannabis markets build lasting trust.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

Today’s cannabis news shows a sector moving into a more institutional and regulated phase.

Market access alone will not build long-term credibility.

As cannabis policy and legal markets evolve, the bigger test will be whether the sector can advance with clear rules, product standards, potency controls, testing, consumer safety, and responsible oversight.

That is where science and compliance matter most.

https://t.co/a01RJvVTIZ

$CBIH #CannabisPolicy #CannabinoidScience #Biotech #ConsumerSafety

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@AMartinelliWA Growth in regulated cannabis markets should continue to be matched with strong standards.

Product consistency, testing, labeling, consumer safety, and responsible compliance are essential for building long-term credibility as legal markets expand.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@MarijuanaMoment Legalization is only one part of building a credible cannabis market.

Clear rules, licensing structures, product standards, consumer safeguards, and responsible oversight are what help regulated markets develop with long-term stability.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

Technology can support compliance, but responsible market development still depends on clear, enforceable standards.

Packaging, labeling, product consistency, age-appropriate safeguards, and consumer safety controls are central to building credible regulated cannabinoid markets.

$CBIH #CannabisPolicy #ConsumerSafety #CannabinoidScience #Biotech

[Marijuana Moment @MarijuanaMoment]

California Marijuana Regulators Unveil New AI Tool To Prevent Product Packaging That May Appeal To Kids: Cannabis businesses can "simply snap a photo using their smart phone or mobile device."

https://t.co/3S1git8bp1

[Cannabis Bioscience International Holdings Inc @CBIHMD]

Emerging cannabinoid research should continue to be evaluated with scientific discipline.

For complex medical areas, rigorous study design, patient safety, careful interpretation, and evidence-based oversight are essential before research findings can inform responsible therapeutic development.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

Medical cannabis policy should continue moving toward science-based evaluation, patient access, and responsible implementation.

As federal and state frameworks evolve, the sector will need regulatory clarity, safety standards, product consistency, and evidence-based oversight.

That is how regulated medical cannabis earns long-term credibility.

$CBIH #MedicalCannabis #CannabinoidScience #CannabisPolicy #Biotech

[NORML @NORML]

🚨 Medical cannabis rescheduling was a long-overdue step forward. Now Indiana and Nebraska officials are asking a federal court to reverse it.

The lawsuit challenges the order moving state-authorized medical cannabis products from Schedule I to Schedule III under federal law.

🔗 Read more: https://t.co/OAtufPVgWi

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@AMartinelliWA Medical cannabis policy works best when access is paired with responsible implementation.

Licensing structures, product standards, compliance, consumer safety, and clear oversight are essential for building credible regulated markets.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@NL_Times Regulated cannabis markets require more than legal access.

Clear rules, product standards, testing, compliance, and consumer safeguards are what help create credible and responsible market structures.

[Cannabis Bioscience International Holdings Inc @CBIHMD]

@todd_harrison Regulated cannabis markets require more than legalization.

Clear rules, product standards, testing, compliance, and consumer safeguards are what help separate structured markets from informal ones.